{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:21:45Z","timestamp":1778775705201,"version":"3.51.4"},"reference-count":11,"publisher":"Elsevier BV","issue":"19","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.vaccine.2014.01.073","type":"journal-article","created":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T20:00:33Z","timestamp":1394136033000},"page":"2217-2224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax\u00ae regimen for post-exposure prophylaxis in healthy adults"],"prefix":"10.1016","volume":"32","author":[{"given":"Robert J.","family":"Hopkins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cris","family":"Howard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ericka","family":"Hunter-Stitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina E.","family":"Kaptur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Pleune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Muse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Sheldon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Strout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katya","family":"Vert-Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.01.073_bib0005","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis","volume":"20","author":"Ionin","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.01.073_bib0010","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.300.13.1532","article-title":"Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial","volume":"300","author":"Marano","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2014.01.073_bib0015","series-title":"National Center for Immunizations and Respiratory Diseases. Anthrax Vaccine Adsorbed: Human Reactogenicity and Immunogenicity Trial to Address. Change in Route of Administration and Dose Reduction (AVA.000). Final clinical study report. December 1","author":"Wright","year":"2009"},{"key":"10.1016\/j.vaccine.2014.01.073_bib0020","unstructured":"BioThrax prescribing information. Available from: http:\/\/www.biothrax.com\/prescribinginformation_biothrax_us.pdf; May 2012 [accessed 03.07.13]."},{"key":"10.1016\/j.vaccine.2014.01.073_bib0025","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/CVI.00003-08","article-title":"Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species","volume":"15","author":"Omland","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.01.073_bib0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J Immunol Methods"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2014.01.073_bib0035","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3201\/eid0810.020380","article-title":"Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen","volume":"8","author":"Quinn","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.073_bib0040","series-title":"Battelle validation VP 2008-220, validation for the human anti-PA IgG Enzyme Linked Immunosorbent Assay (ELISA). May 9","author":"Rudge","year":"2011"},{"key":"10.1016\/j.vaccine.2014.01.073_bib0045","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/009286159603000228","article-title":"Statistical considerations for multiplicity in confirmatory protocols","volume":"30","author":"Koch","year":"1996","journal-title":"Drug Inf J"},{"issue":"151","key":"10.1016\/j.vaccine.2014.01.073_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3004073","article-title":"Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge","volume":"4","author":"Fay","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2014.01.073_bib0055","unstructured":"www.clinicaltrials.gov [NCT01753115]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14001364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14001364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T02:05:23Z","timestamp":1565229923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14001364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":11,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0264410X14001364"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.01.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax\u00ae regimen for post-exposure prophylaxis in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.01.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}